Impax Opens New Front In Adderall Battle With Shire

Law360, New York (November 11, 2005, 12:00 AM EST) -- Impax Laboratories Inc. is taking action against the newest patent issued for anti-depressant Adderall XR, countersuing Shire Laboratories Inc. in federal court. At the same time, Shire is lobbying the FDA to further restrict the generic manufacture of the drug.

California-based Impax is seeking a declaratory judgment that it does not infringe Maryland-based Shire’s Adderall patent and that the patent’s claims are invalid. The suit was filed in the U.S. District Court for the District of Delaware.

Shire sued Impax, as well as Barr Laboratories Inc.,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.